RN-014：常染色體顯性多囊腎病（ADPKD） 是最常見的遺傳性且難治性疾病，其特徵為腎臟內逐漸形成大量囊腫，最終導致末期慢性腎衰竭。

本公司利用疾病專一性 iPS 細胞所建立的人類疾病模型，成功發現針對 ADPKD 的小分子治療藥物。
 
目前唯一獲准治療 ADPKD 的藥物為 tolvaptan，儘管副作用嚴重，其年銷售額仍高達 15 億美元。

基於此，我們的產品具有成為「同類首創（first-in-class）且首線治療（first-line）」藥物的潛力。

預計將根據正在進行中的第二期臨床試驗結果，於 2025 年底前獲得有關本候選藥物療效的實質證據。

RN-014: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common hereditary and intractable disease characterized by the progressive formation of numerous renal cysts, leading to end-stage chronic kidney failure.

A small-molecule therapeutic for ADPKD was discovered through a human disease model using disease-specific iPS cells. Despite severe side effects, the only treatment option, tolvaptan, generates sales of $1.5 billion.

Given this, our product has the potential to be a first-in-class and first-line therapy.

We aim to obtain evidence of our therapeutic candidate's efficacy by the end of 2025, based on results from our ongoing Phase 2 clinical trial.